Monkeypox Testing Market Size & Growth Forecast 2026–2035, By Segments (Technology Type, End-use Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Monkeypox Testing Market size was over USD 2.08 Million in 2025 and is likely to grow at a 4.5% CAGR between 2026 and 2035, exceeding USD 3.23 Million by 2035. The industry revenue for 2026 is calculated at USD 2.16 million.

• Base Year Value (2025): USD 2.08 Million
• CAGR (2026-2035): 4.5%
• Forecast Year Value (2035): USD 3.23 Million
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Monkeypox Testing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 42.45% of the market in 2025, supported by advanced diagnostic infrastructure, strong laboratory capacity, and efficient integration of disease surveillance into healthcare systems.
  • Asia Pacific is projected to grow at a 5.13% CAGR, driven by expanding diagnostic access, stronger public health monitoring, and greater investment in outbreak preparedness and molecular testing capabilities.

• Segment Momentum:

  • PCR held the largest share in 2025 due to its high diagnostic accuracy, established laboratory integration, and critical role in confirmatory testing for clinical and public health decision-making.
  • LFA is the fastest-growing segment as demand rises for rapid, decentralized testing solutions that enable quicker screening and easier deployment outside traditional laboratory settings.

• Market Expansion Drivers:

  • Government-led outbreak surveillance programs increasing diagnostic testing demand.
  • Advancements in PCR-based diagnostics improving accuracy and testing scalability.
  • Expansion of decentralized rapid testing infrastructure strengthening epidemic preparedness.

• Leading Market Participants:

  Key companies in the monkeypox testing market include Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), Becton, Dickinson and Company (United States), Mayo Clinic Laboratories (United States), Aegis Sciences Corporation (United States), Chembio Diagnostics, Inc. (United States), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 2.08 Million
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 3.23 Million by 2035
  • Growth Forecasts: 4.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Polymerase Chain Reaction (PCR) (Technology Type) | Hospitals & Clinics (End-use Type)
  • Emerging Opportunity Segment: Lateral Flow Assay (LFA) (Technology Type) | Diagnostic Laboratories (End-use Type)

Market Growth Drivers and Industry Trends

Government-led outbreak surveillance programs increasing diagnostic testing demand

When public health agencies intensify case finding, contact tracing, and targeted screening during suspected outbreaks, procurement of monkeypox assays rises quickly because surveillance protocols depend on laboratory confirmation rather than symptom-based reporting alone. In the monkeypox testing market, this creates concentrated demand from government laboratories, hospital networks, and designated reference centers, while also shaping purchasing decisions around throughput, reporting speed, and compatibility with national surveillance systems. Routine monitoring of exposed populations and high-risk clusters supports repeat testing volumes, which in turn reinforces supplier activity in reagents, sample collection kits, and laboratory services tied to outbreak response.

Advancements in PCR-based diagnostics improving accuracy and testing scalability

Improved PCR assay design is strengthening adoption in the monkeypox testing market by reducing cross-reactivity concerns, enhancing sensitivity, and enabling more dependable differentiation of monkeypox from clinically similar infections. This matters in practice because laboratories and healthcare systems are more willing to expand testing when results can support treatment pathways, isolation decisions, and public health reporting with greater confidence. As PCR platforms become easier to integrate into existing molecular workflows, providers can increase testing capacity without building entirely new diagnostic infrastructure, aiding market expansion through higher utilization of installed instruments and recurring consumables demand.

Expansion of decentralized rapid testing infrastructure strengthening epidemic preparedness

The shift toward decentralized testing networks is influencing the monkeypox testing market by moving diagnostic access closer to community clinics, regional hospitals, and outbreak hotspots where early triage decisions are made. Faster availability of testing outside central reference laboratories shortens the time between symptom presentation and confirmation, which encourages broader operational use during containment efforts and supports more responsive local surveillance. This infrastructure buildout also changes purchasing behavior, as health systems and public agencies prioritize portable platforms, simplified workflows, and training-compatible solutions that can be deployed quickly during periods of heightened epidemiological risk.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Government-led outbreak surveillance programs increasing diagnostic testing demand	2.00%	High	North America, Europe	Medium	Near Term
Advancements in PCR-based diagnostics improving accuracy and testing scalability	1.50%	High	North America, Europe	High	Near Term
Expansion of decentralized rapid testing infrastructure strengthening epidemic preparedness	1.20%	High	Global	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading position in 2025, accounting for a 42.45% share of the monkeypox testing market. This leadership is supported by the region’s established diagnostic infrastructure, broad laboratory testing capacity, and faster integration of infectious disease surveillance into routine clinical and public health workflows. In practice, that means suspected cases can move more quickly from identification to confirmatory testing, while healthcare providers and public agencies are better positioned to sustain demand for accurate assays, reagents, and related testing services.

Asia Pacific is projected to expand at a 5.13% CAGR over the forecast period in the monkeypox testing market, driven by the ongoing strengthening of public health monitoring and the gradual expansion of diagnostic access across healthcare systems. Growth is being accelerated by rising attention to outbreak preparedness, which is encouraging wider use of molecular testing capabilities and improving the ability of hospitals, reference laboratories, and health authorities to respond when case detection requirements increase.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Medium	High	Medium	High	High
Regulatory Environment	Supportive	Restrictive	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Public Health Preparedness

The U.S. continues strengthening monkeypox testing capacity through expanded laboratory networks and rapid molecular diagnostics. Healthcare providers in the U.S. prioritize timely case identification and scalable testing capabilities to support outbreak response efforts.

Japan

Diagnostic Quality Standards

Japan focuses on highly reliable monkeypox testing supported by rigorous laboratory quality requirements. Diagnostic providers in Japan prioritize validated testing methods and efficient integration with national infectious disease monitoring systems.

South Korea

Rapid Response Diagnostics

South Korea continues enhancing monkeypox testing readiness through advanced molecular diagnostic capabilities and responsive laboratory infrastructure. Healthcare organizations in South Korea prioritize fast turnaround times and coordinated surveillance for suspected cases.

Germany

Laboratory Network Expansion

Germany reinforces monkeypox testing through coordinated diagnostic laboratories and standardized testing protocols. Healthcare institutions across Germany emphasize accurate molecular diagnostics and efficient sample processing to strengthen infectious disease surveillance.

France

Integrated Disease Surveillance

France supports monkeypox testing through coordinated public health laboratories and strengthened infectious disease monitoring. Healthcare authorities in France emphasize accessible diagnostics and effective reporting systems to improve outbreak management capabilities.

Italy

Clinical Testing Readiness

Italy continues improving monkeypox testing availability across hospital laboratories and reference diagnostic centers. Healthcare providers in Italy prioritize dependable molecular testing and coordinated laboratory workflows to support timely clinical decision-making and public health monitoring.

Segment Leadership and Growth Trends

  Technology Type Segment Analysis: Polymerase Chain Reaction (PCR) (Largest Segment) vs Lateral Flow Assay (LFA) (Fastest-Growing Segment)

Polymerase Chain Reaction (PCR) held the largest share of the monkeypox testing market in 2025, reflecting its central role in confirmatory diagnosis where accuracy and clinical reliability are critical. PCR remains the leading technology because healthcare providers and testing centers rely on it for pathogen-specific detection, especially in settings where diagnostic certainty guides isolation decisions, treatment pathways, and public health response. Its established use within laboratory workflows and compatibility with existing molecular testing infrastructure continue to support its leadership in the monkeypox testing market.

Lateral Flow Assay (LFA) is emerging as the fastest-growing technology segment in the monkeypox testing market because it addresses the practical need for quicker and more accessible testing outside complex laboratory environments. Growth is being encouraged by rising demand for rapid screening in decentralized care settings, where ease of use and faster turnaround can improve early identification and response. Compared with PCR, LFA is gaining momentum where operational simplicity and speed matter more than full laboratory processing, making it increasingly attractive for broader deployment.

End-use Type Segment Analysis: Hospitals & Clinics (Largest Segment) vs Diagnostic Laboratories (Fastest-Growing Segment)

In 2025, Hospitals & Clinics accounted for the largest share of the monkeypox testing market, backed by their position as the first point of care for patients presenting with suspected symptoms. This segment leads because testing decisions are often initiated in clinical settings where patient evaluation, sample collection, and immediate case management occur together. Hospitals and clinics also remain central to the monkeypox testing market due to their direct role in managing infection control protocols and coordinating timely diagnosis within routine care delivery.

Diagnostic Laboratories represent the fastest-growing end-use segment in the monkeypox testing market as testing volumes increasingly move toward facilities built for scalable processing and standardized diagnostic workflows. Their growth is tied to the need for higher throughput, stronger technical specialization, and more efficient handling of confirmatory testing as demand becomes more structured. Relative to hospitals and clinics, diagnostic laboratories are gaining momentum because they are better positioned to expand dedicated testing capacity while maintaining consistency across larger sample loads.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Technology Type	Polymerase Chain Reaction (PCR), Lateral Flow Assay (LFA), Others	Polymerase Chain Reaction (PCR)	Lateral Flow Assay (LFA)
End-use Type	Hospitals & Clinics, Diagnostic Laboratories, Others	Hospitals & Clinics	Diagnostic Laboratories

Competitive Landscape and Market Positioning

Key companies in the monkeypox testing market:

1. Thermo Fisher Scientific Inc. (United States)

2. QIAGEN N.V. (Netherlands)

3. Quest Diagnostics Incorporated (United States)

4. Laboratory Corporation of America Holdings (United States)

5. Becton Dickinson and Company (United States)

6. Mayo Clinic Laboratories (United States)

7. Aegis Sciences Corporation (United States)

8. Chembio Diagnostics Inc. (United States)

9. Abbott Laboratories (United States)

10. F. Hoffmann-La Roche Ltd (Switzerland)

Diagnostic accuracy improvements are driving innovation in testing methodologies. Faster detection and broader accessibility are key priorities across healthcare systems. In the monkeypox testing market, reliability and rapid response capabilities remain central to development efforts.

Industry Development/News

Company Name	Date	Key Development
CerTest Biotec	Jun-22	CerTest Biotec partnered with BD (Becton, Dickinson and Company) to develop a molecular diagnostic test for monkeypox using the BD MAX open system reagent platform. The collaboration expands access to validated diagnostic solutions and strengthens molecular testing capabilities for infectious disease detection within global laboratory networks.
Quest Diagnostics	Sep-22	Quest Diagnostics received U.S. FDA emergency use authorization for its lab-developed molecular diagnostic test for monkeypox infection. The approval enabled commercialization of its testing solution, expanding its infectious disease diagnostics portfolio and supporting broader laboratory-based detection capacity during outbreak conditions.
Global Health Innovative Technology Fund	Dec-25	The Global Health Innovative Technology Fund invested JPY 70 million to advance development of a prototype mpox detection assay. The funding supports early-stage diagnostic innovation aimed at improving detection capabilities and strengthening global preparedness for mpox-related infectious disease monitoring.
South African Health Products Regulatory Authority	May-25	The South African Health Products Regulatory Authority listed the first mpox in-vitro diagnostic through the WHO reliance pathway. The regulatory approval expands availability of standardized diagnostic testing within national healthcare systems, supporting improved disease surveillance and laboratory diagnostic capacity.